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Abstract
The immunocytokine scFvMEL/TNF, a fusion protein
composed of human tumor necrosis factor (TNF) and a
single-chain Fv antibody (scFv) scFvMEL targeting the
melanoma gp240 antigen, demonstrates impressive
cytotoxic effects against human melanoma cell lines
in vitro. Pharmacokinetic studies of 125I-scFvMEL/TNF
in BALB/c mice showed that the construct clears
from the circulation with a terminal-phase half-life of
17.6 hours after intravenous administration. The maxi-
mum tolerated dose of scFvMEL/TNF in nude mice was
4 mg/kg, i.v., on a daily 5 schedule. There were no
changes ingrosspathology, clinical chemistry, or hema-
tologic parameters in mice treated at doses of up to
3 mg/kg. Therapeutic studies at a dose of 2.5 mg/kg on
athymic mice bearing established (~ 50 mm3) human
melanoma A375GFP xenograft tumors transfected with
green fluorescent protein demonstrated potent tumor
suppression and complete tumor regression of all le-
sions. There was no subsequent outgrowth of tumors
from mice rendered tumor-free. These data show that
scFvMEL/TNF can target melanoma cells in vivo and
can result in pronounced antimelanoma effects after
systemic administration. Toxicology studies indicate
the relative safety of this agent at doses that are thera-
peutically effective and provide guidance to projected
phase I starting doses on patients at this schedule.
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Introduction
Through molecular engineering, proteins can be modified to
significantly enhance their biologic activities. There have
been numerous fusion proteins designed to combine the
specific cell-binding characteristics of antibodies or growth
factors with the cytotoxic or growth-modulatory effects of
toxins, cytokines, or proapoptotic proteins [1–4]. Studies
by Pastan and Kreitman [5], Pastan [6], Chan and Murphy [7],
Murphy et al. [8], Reisfeld et al. [9,10], Xiang et al. [11],
Rosenblum [1], Rosenblum et al. [12,13], and Dadachova
et al. [14] have all demonstrated the preclinical and clinical
potentials of these hybrid molecules.
The high-molecular-weight melanoma-associated glyco-
protein gp240 has previously been demonstrated in a majority
(80%) of melanoma cell lines and fresh tumor samples [15].
Recently, the gp240 antigen was found in 44 of 66 lobular breast
cancer biopsy specimens [16], suggesting a possible common
origin for some types of breast cancer and melanoma. More
importantly, the gp240 antigen is either not expressed or ex-
pressed in low levels in normal cells [17,18], thus making this
an interesting target for therapeutic intervention. Monoclonal
antibodies (mAbs) targeting the gp240 antigen, such as ZME-
018 and 9.2.27, have been extensively studied in melanoma
patients and have demonstrated in numerous clinical trials
an impressive ability to localize in metastatic tumors after sys-
temic administration [19,20].
The antibody ZME-018 possesses high specificity for mel-
anoma and is minimally reactive with a variety of normal
tissues, making it a promising candidate as a targeting carrier
[12,19,21,22]. Full-length mAbs are capable of selectively
targeting tumor cells while avoiding normal tissues and are
able to kill tumor cells through a variety of intrinsic (immuno-
logic) and extrinsic (by the use of carried cytotoxic agents)
modes. However, these molecules are large, poorly diffusible
into areas of bulky disease, and highly immunogenic, render-
ing repeated infusions problematic. These advantages and
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disadvantages must be carefully considered in the applica-
tion of mAb in cancer treatment.
Single-chain Fv antibodies (scFvs) consist of the antibody
VL and VH domains linked by a designed flexible peptide
tether [23]. Compared to intact IgG, scFvs have the following
advantages: 1) smaller size; 2) structural simplicity with
comparable antigen-binding affinities; 3) stability greater than
that of analogous two-chain Fab fragments [24,25]. Several
studies have shown that the smaller size of scFvs provides
better penetration into tumor tissues, improved pharma-
cokinetics, and reduction in the immunogenicity observed
with intravenous administration of Fabs, compared to that of
intact murine antibodies [24–27].
The single-chain antibody scFvMEL retains the same
binding affinity and specificity of the parental ZME-018 anti-
body, which recognizes the surface domain of the gp240
antigen [15,19]. It has been used extensively in our laboratory
to target gp240-bearing cells in vitro and using xenograft
models [3,12,20,28–31]. This antibody binds to target cells
and is efficiently internalized, making this an excellent di-
rect carrier of toxins or other cytotoxic payloads to gp240
antigen–positive cells.
Tumor necrosis factor (TNF) is a cytotoxic polypeptide that
is secreted primarily by activatedmacrophages, and it shares
some sequence homology (30%) with another peptide hor-
mone, lymphotoxin (LT or TNF-b), which is secreted by acti-
vated lymphocytes [32]. Purified recombinant human (rhu)
TNF-a is a single-chain nonglycosylated polypeptide with a
molecular mass of 17 kDa, although it polymerizes into a
compact non–disulfide-linked trimer in solution. TNF medi-
ates a wide spectrum of systemic and cellular responses, in-
cluding fever, shock, tissue injury, tumor necrosis, induction
of other cytokines and immunoregulatory molecules, cell pro-
liferation, differentiation, and apoptosis [33]. In vitro, TNF is
cytostatic or cytotoxic to a number of human tumor cells,
including SKBR-3 breast carcinoma and A375-M human
melanoma [34,35]. However, the use of TNF in cancer ther-
apy is restricted by severe dose-limiting toxicity and limited
clinical efficacy against many tumor types [32]. A variety of
strategies have been suggested for the use of the antitumor
properties of this agent and for the simultaneous reduction of
its systemic side effects, including the transfer of the TNF
gene into tumor cells [36], tumor-infiltrating lymphocytes [37],
and endothelial cells lining the artery, leading to local gener-
ation of TNF [38], stimulation of the local synthesis of TNF
in situ [39], and antibody-mediated delivery [4,28,40,41].
Previous studies in our laboratory initially demonstrated
that immunocytokines consisting of chemical conjugates of
human TNF and mAbs displayed impressive targeted cyto-
toxic properties against tumor cells in culture, appeared to be
cytotoxic agents that are far superior to native TNF, and were
active against TNF-resistant tumor cells [4,12,28]. In addition,
studies in xenograft models suggested that antibody–TNF
conjugates readily accumulate specifically in tumor tissues
and demonstrate in vivo antitumor activity that is superior
to that of native TNF [12]. Based on these original observa-
tions, we designed and constructed a second-generation
recombinant fusion construct composed of the recombinant
single-chain anti-gp240 antibody scFvMEL that targets human
melanoma cells and contains human TNF as a cytotoxic
effector molecule, designated scFvMEL/TNF [4]. This fusion
protein, compared to native TNF, was shown to enhance the
in vitro killing of both TNF-sensitive and TNF-resistant human
melanoma cells. In addition, radiolabeled scFvMEL/TNF was
shown to localize effectively in human melanoma xenografts
after intravenous administration.
The purpose of the current study was to evaluate the
in vivo pharmacokinetics, toxicity, and therapeutic effects of
scFvMEL/TNF in murine models to identify parameters that
are critical for the clinical development of this agent.
Materials and Methods
Cell Lines
A375-M (humanmelanoma, gp240 antigen–positive, TNF-
sensitive), AAB-527 (human melanoma, gp240 antigen–
positive, TNF-resistant), SKBR3-HP (human breast cancer,
gp240-negative, TNF-sensitive), and H4 (human neuro-
glioma, gp240-negative, TNF-resistant) were maintained in
culture using Dulbecco’s modified Eagle’s medium (DMEM)
with 10% fetal bovine serum (FBS) containing antibiotics
(0.05 mg/ml), added glutamine (2 mM), sodium pyruvate
(1 mM), nonessential amino acids (0.1 mM), and MEM
vitamins specific for A375-M and AAB-527. All cells were
routinely grown at a density of 7  106 cells per T-75 flask,
subcultured twice weekly, routinely tested, and found to be
free of Mycoplasma contamination using Mycoplasma Plus
PCR Primer Sets (Stratagene, Cedar Creek, TX). Tissue cul-
ture media and supplements were purchased from Life Tech-
nologies, Inc. (Rockville, MD).
Stable Transfection of A375 Cell Lines
The plasmid pcDNA3-EGFP was produced by inserting a
HindIII/XhoI fragment containing the enhanced green fluo-
rescent protein (EGFP) coding sequence from pCMV-EGFP
into the same sites of pcDNA3.1. Lipofectamine 2000 reagent
(Invitrogen Life Technologies, Carlsbad, CA) was used for
transfection. Briefly, cells were cultured for 24 hours in six-
well plates with 1 ml/well DMEM with 10% FBS until 60%
to 70% confluence had been reached. Liposomal DNA
(Lipofectamine–pcDNA3–GFP complex) or nonliposomal
DNA (pcDNA3) was directly added into culture plates at
a proportion of 2 mg of DNA per 106 cells. To produce A375
cells that stably express EGFP, G418 (400 mg/ml) selection
was started 24 hours after transfection. After 10 days of se-
lection with G418, surviving cells were examined by fluo-
rescence microscopy. Fluorescent colonies were picked
and expanded. Cellular expression of GFP was evaluated
using a fluorescence/visible light microscope setup to di-
rectly assess the percentage of total cells fluorescing. The
stable transfection clone A375GFP-B1 was further charac-
terized, including its response to TNF and scFvMEL/TNF,
and the expression of the gp240 antigen was compared
to that of the parental cell line. This clone was then used for
in vivo studies.
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Production of scFvMEL/TNF, scFvMEL, and rhuTNF
The scFvMEL/TNF fusion gene was constructed using
polymerase chain reaction–based construction methods.
The fusion gene was finally cloned into a bacterial ex-
pression vector pET32a(+) (Novagen, Madison, MI), and
soluble fusion protein was expressed and purified as pre-
viously described [4].
The rhuTNF gene from plasmid pET32scFvMEL/TNFwas
subcloned into the pET32a(+) vector, and the protein was
expressed in Escherichia coli Origami (DE3) cells. The ex-
pression and purification of TNF were the same as those of
the fusion protein scFvMEL/TNF. The biologic activity of TNF
was assessed using a standard biologic assay, which de-
pends on cytotoxicity to a standard L-929 murine fibroblast
cell line, as previously described [28]. rhuTNFa (Roche Mo-
lecular Biochemicals, Indianapolis, IN) was used as stan-
dard. The biologic activity of the final purified huTNF was
2 10 7 U/mg protein.
The scFvMEL gene was amplified by polymerase chain
reaction from plasmid pET32scFvMEL/TNF, and the
gene was cloned into the pET21b vector, creating plasmid
pET21scFvMEL. The scFvMEL protein was expressed in
E. coli AD494 (DE3) plysS. Biologically active scFvMEL pro-
tein was obtained by refolding an insoluble inclusion body
based on a procedure described by Steinle et al. [42]. The final
purified scFvMEL protein was shown to have target antigen–
binding activity, as assessed by enzyme-linked immuno-
sorbent assay [4], which was identical to that of the scFvMEL/
TNF construct.
In Vitro Cytotoxicity of scFvMEL/TNF and TNF
To examine the cytotoxicity of scFvMEL/TNF and TNF,
cells were plated into 96-well plates at a density of 3000 cells/
well and allowed to adhere for 24 hours at 37jC in 5% CO2.
After 24 hours, the medium was replaced with one containing
different concentrations of either scFvMEL/TNF or TNF. The
effect of scFvMEL/TNF and TNF on the growth of tumor cells
in culture was determined by crystal violet (0.5% in 20%
methanol) staining and was solubilized with Sorenson’s
buffer (0.1 M sodium citrate, pH 4.5, in 50% ethanol), as
previously described [28]. Cell plates were read at 630 nm
(Bio-Tek Instruments, Winooski, VT). Percent control refers
to the percentage of cells in drug-treated wells compared to
that in control (untreated) wells.
Protein Labeling Using p-Iodobenzoate
Proteins were labeled with 125I (Dupont, Wilmington, DE)
by the p-iodobenzoate method, as previously described [12].
Animal Model Studies
Pharmacokinetic study Female BALB/c mice (4–6 weeks
old) were injected with 5 mg of total protein in 200 ml of normal
saline (2 mCi of 125I-scFvMEL/TNF per mouse). At 1, 2, 4, 8,
24, 48, and 72 hours after injection, three mice were sacrificed
by cervical dislocation at each assay time. Blood samples
were removed from the chest cavity, weighed, and counted to
determine the total radioactivity in a g-counter (model 5360;
Packard, Meriden, CT). The blood samples were also centri-
fuged, and plasma was decanted and counted to determine
radioactivity. The results from plasma determinations of radio-
activity were analyzed by a least squares nonlinear regression
(PK Analyst; MicroMath, Inc., St. Louis, MO) program.
In vivo toxicity study To determine the maximum tolerated
dose (MTD) and the lethal dose (LD) for scFvMEL/TNF,
female BALB/c mice (4–6 weeks old) were assigned to
six groups (three to five mice per group). scFvMEL/TNF, at
six total doses per group, was administered through the tail
vein daily for 5 days, and mice were observed everyday
to establish the MTD and the LD. The MTD was defined as
the highest total dose that could be administered without le-
thality. Then, five groups (five mice per group) of female
BALB/c mice (4–6 weeks old) were treated (intravenously
through the tail vein) with either saline or four doses of the
drug, using the same schedule. The total doses admini-
stered to each group were 1, 2, 3, and 4 mg/kg, and these
doses corresponded to 25%, 50%, 75%, and 100% of the
previously established MTD. Seven days after the last injec-
tion (day 12), the animals were sacrificed with carbon dioxide;
terminally bled for hematologic parameters [including com-
plete blood count (CBC)] and clinical chemistry analysis
[including sodium, potassium, calcium, phosphorus, chloride,
total bilirubin (TBIL), total protein (TP), albumin (Alb), globulin
(Glob), alkaline phosphatase (Alk), creatinine (Cr), blood
urea nitrogen (BUN), aspartate aminotransferase (AST),
and alanine aminotransferease (ALT)]; and subjected to com-
plete necropsy. Sections of the heart, lungs, spleen, kidneys,
liver, gallbladder, skeletal muscles, aorta, brain, pituitary
gland, eyes, lacrimal glands, sciatic nerve, spinal cord, pan-
creas, stomach, duodenum, jejunum, ileum, cecum, colon,
rectum, lymph nodes (mesenteric and mandibular), thymus,
adrenal gland, larynx/pharynx, tongue, thyroid gland, para-
thyroid glands, trachea, esophagus, injection site, skin, mam-
mary glands, urinary bladder, ovary, uterus, cervix, femur with
knee joint, sternum, and bone marrow were fixed by immer-
sion in a neutral-buffered 10% formalin solution. The tissues
were embedded in paraffin blocks, sectioned at a nominal
5-mm section, stained with hematoxylin and eosin, and ex-
amined by a certified veterinary pathologist at the Depart-
ment of Veterinary Medicine and Surgery of the University of
Texas M. D. Anderson Cancer Center (Houston, TX).
In vivo efficacy study BABL/c (nu/nu) mice (4–6 weeks
old) were injected subcutaneously with 3  106 A375GFP
log-phase melanoma cells in the right flank. The tumors were
allowed to establish for 2 weeks before the start of therapy,
and the mice were divided into four groups. Each group had
five mice with 30- to 50-mm3 established tumors. The mice
were injected (intravenously through the tail vein) daily for
5 days with saline, scFvMEL (2.5 mg/kg), scFvMEL (0.2 mg/
kg) plus TNF (0.2 mg/kg), or scFvMEL/TNF (2.5 mg/kg, 60%
MTD). At the end of the therapy, the tumors were monitored
weekly using Xenogen IVIS 200 Imaging System (Xenogen
Co., Alameda,CA) and every 2 or 3 dayswith a caliper. Tumor
volume was calculated with the formula: tumor volume =
(width)2  length/2 [43].
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Statistical Analysis
Data were analyzed using paired t-test (Prism 3.0; Micro-
Math, Inc., St. Louis, MO). Data are presented as mean ±
SEM. A difference was regarded as significant if P < .05.
Results
Cytotoxicity of scFvMEL/TNF In Vitro
The cytotoxicity of scFvMEL/TNF was assessed against
log-phase antigen-positive, TNF-sensitive human melanoma
A375-M cells and antigen-positive, TNF-resistant human
melanoma AAB-527 cells, respectively. We also compared
these effects with antigen-negative, TNF-sensitive human
breast cancer SKBR3-HP and antigen-negative, TNF-
resistant human neuroglioma H4 cells. The results showed
that, against antigen-positive A375-M cells, scFvMEL/TNF
(IC50 = 0.1 nM) appeared to be approximately 10-fold more
active than native TNF (IC50 = 1.4 nM) (P < .0001). Against
TNF-sensitive, antigen-negative SKBR3-HP cells, the cyto-
toxicity of scFvMEL/TNF (IC50 = 2.5 nM) showed a dose–
response curve similar to that of authentic TNF (IC50 = 2.7 nM)
(P > .05). Against antigen-negative, TNF-resistant H4 cells,
scFvMEL/TNF demonstrated no cytotoxic effects at doses
of up to 1000 nM. However, against antigen-positive, TNF-
resistant human melanoma AAB-527 cells, scFvMEL/TNF
showed significant dose-related cytotoxic effects (IC50 =
20 nM). In contrast, these AAB-527 cells were resistant
to the cytotoxic effects of TNF at concentrations of up to
5000 nM (Table 1). These results demonstrate that scFvMEL/
TNF appeared to be significantly more active than native
TNF against gp240 antigen–positive cells. More importantly,
the fusion construct appeared to be able to overcome
TNF resistance on gp240 antigen–positive, TNF-resistant
AAB-527 cells.
In Vivo Pharmacokinetics of scFvMEL/TNF
As described in the Materials and Methods section,
scFvMEL/TNF was radiolabeled using the p-iodobenzoate
method. The blood samples from BALB/c mice were centri-
fuged, and plasma was decanted and counted to determine
radioactivity at different time points after injection. The re-
sults from plasma determinations of radioactivity were ana-
lyzed by a least squares nonlinear regression program.
Pharmacology studies of scFvMEL/TNF in mice show a tri-
phasic clearance curve with calculated plasma half-lives
of 0.38, 3.9, and 17.6 hours for the a, b, and g phases, re-
spectively (Figure 1). The immediate apparent volume of
distribution (Vd) of scFvMEL/TNF was 19.5 ml. However, the
plasma clearance of radiolabeled TNF, chemical conjugate
ZME–TNF, and intact antibody ZME was biphasic and
closely fit (c2 > 0.94) an open two-compartment mathe-
matical model. Comparatively, as shown in Table 2, the
half-lives of full-length antibody ZME-018 and chemical con-
jugate ZME–TNF were similar in this model, with a-phase
half-lives of 1.39 and 1.2 hours, respectively. In addition, the
half-lives of the terminal phases were also similar at 41.3 and
36.1 hours, respectively. In contrast, the clearance of free
TNF in this model was relatively rapid, with a-phase and
b-phase half-lives of 27.1 minutes and 2.7 hours, respec-
tively. The immediate apparent volume of distribution (Vd) for
ZME-018 alone approximated the blood volume (1.9 ml),
whereas TNF alone had a somewhat larger Vd (3.9 ml).
The chemical conjugate ZME–TNF displayed a Vd (11.6 ml)
that was higher that that of either ZME-018 or TNF, suggest-
ing a greater distribution outside the vasculature. The fusion
construct scFvMEL/TNF demonstrated the highest Vd
(19.5ml), suggesting the most extensive extravascular dis-
position in all of its component agents.
Toxicity Studies of scFvMEL/TNF in BALB/c Mice
MTD and LD for scFvMEL/TNF The total doses of
scFvMEL/TNF per group of mice administered through
the tail vein daily for 5 days are 16.7, 8.3, 4.8, 4.0, 2.5, and
0.5 mg/kg, respectively. The percentages of deaths and sur-
vivors are summarized in Table 3. The LD25 of scFvMEL/
TNF in mice was approximately 4.8 mg/kg. The LD100 of
scFvMEL/TNF in mice was approximately 8.3 mg/kg. The
MTD of scFvMEL/TNF in mice was the highest dose in which
no drug-related deaths were noted and was approximately
4.0 mg/kg.
Mortality, gross pathology, and organ weight For mice
treated at doses of up to and including the MTD, no deaths
occurred in this study. In addition, there were no dose-related
gross pathology findings observed even at the MTD level. A
few gross lesions that were considered incidental and unre-
lated to the administration of scFvMEL/TNF were observed.
scFvMEL/TNF caused a dose-related increase in relative
spleen weights (relative to body weight) at doses of 1, 2, 3,
Table 1. Cytotoxicity* of scFvMEL/TNF Versus TNF on Various Human Cell Lines.
Cell Lines Cell Features IC50 of
scFvMEL/TNF
(nM)
IC50 of
TNF (nM)
Targeting
Indexy
P
A375-M gp240+, TNF-sensitive 0.1 ± 0.013 1.37 ± 0.020 15 < .0001
AAB-527 gp240+, TNF-resistant 20.62 ± 1.125 > 5000z > 250 –
SKBR3-HP gp240, TNF-sensitive 2.55 ± 0.085 2.71 ± 0.014 1 > .05
H4 gp240, TNF-resistant > 1000z > 5000z – –
*Seventy-two–hour treatment.
yTargeting index = (IC50 of TNF)/(IC50 of scFvMEL/TNF).
zNo cytotoxic effects at indicated concentrations.
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and 4 mg/kg (Figure 2). The magnitude of the increase
plateaus at 3 mg/kg. The increase in spleen weight corre-
lated with increased extramedullar hematopoiesis in the
red pulp and with increased follicular hyperplasia in the
white pulp.
Clinical pathology No test substance–related alterations
were noted in hematologic parameters [including hemoglo-
bin (HGB), hematocrit (HCT), and CBC] (Table 4) and clinical
chemistry parameters (including sodium, potassium, cal-
cium, phosphorus, TBIL, TP, Alb, Glob, Alk, Cr, and BUN)
(Table 5). There was a very slight increase in the mean
levels of ASTand ALT in the 2-, 3-, and 4-mg/kg groups when
compared to those of the control saline group, but it was still
within the reference range for this study. These minimal
mean elevations in the treated groups were due to single
animals in each group. No histopathologic correlations were
observed in any of these animals, suggesting that elevations
in these three animals may be spurious.
Histopathology Systemic administration of scFvMEL/TNF
resulted in apparent dose-dependent lesions in the liver,
lung, and spleen of female BALB/c mice (Table 6). The
incidence and severity of these lesions appear to be dose-
dependent and include increased extramedullary hemato-
poiesis of the liver and spleen at doses greater than or equal
to 2, 3, and 4 mg/kg scFvMEL/TNF; pulmonary fibrin thrombi
of the lung at doses greater than or equal to 4 mg/kg
scFvMEL/TNF; and follicular hyperplasia of the splenic white
pulp at doses greater than or equal to 1, 2, 3, and 4 mg/kg
scFvMEL/TNF. The most sensitive indicators of scFvMEL/
TNF–related effects appeared to be extramedullary hemato-
poiesis and follicular lymphoid hyperplasia of the spleen.
The no-observed-adverse-effect level (NOAEL) for scFvMEL/
TNF under the conditions of this study is 3 mg/kg, based on
fibrin thrombi observed in the lungs of three of five animals in
the 4-mg/kg group.
The dose-dependent extramedullary hematopoiesis ob-
served was considered compound-related, but was not
considered adverse. The exact mechanism for the increased
extramedullary hematopoiesis is not known, but this can be
caused by factors that stimulate hematopoiesis, such as
proinflammatory proteins. Follicular lymphoid hyperplasia is
considered an immunogenic response to a foreign protein
in mice. This study did not attempt to measure the immuno-
genicity of the protein, which will be addressed in a more
relevant species.
No significant lesions were observed in the kidneys,
gallbladder, heart, skeletal muscles, aorta, brain, pituitary
gland, eyes, lacrimal glands, sciatic nerve, spinal cord, pan-
creas, stomach, duodenum, jejunum, ileum, cecum, colon,
rectum, lymph nodes (mesenteric and mandibular), thymus,
adrenal gland, larynx/pharynx, tongue, thyroid gland, para-
thyroid glands, trachea, esophagus, injection site, skin, mam-
mary glands, urinary bladder, ovary, uterus, cervix, femur
with knee joint, sternum, and bone marrow.
In Vivo Antitumor Effects of scFvMEL/TNF
Groups of mice bearing established (30–50 mm3)
A375GFP xenografts were treated (intravenously through
the tail vein) daily (days 1–5) for 5 days with saline, scFvMEL
(2.5 mg/kg), scFvMEL (0.2 mg/kg) plus TNF (0.2 mg/kg), or
scFvMEL/TNF (2.5 mg/kg). The mice were observed, and
their tumors were imaged by the Xenogen IVIS 200 Imaging
System and measured using a caliper every 2 or 3 days.
Three of five mice on day 16, four of five mice on day 22, and
five of five mice on day 36 had no detectable tumors, as as-
sessed (arrows) by an external imaging system. In contrast,
tumor GFP signals in all mice in the saline and scFvMEL
Figure 1. Pharmacokinetics of 125I-labeled scFvMEL/TNF in mice. The
radiolabeled fusion construct was administered intravenously to BALB/c mice.
Groups (five per group) were sacrificed at various times after administration.
The radioactivity in plasma was assessed, and the results were analyzed by
a least squares nonlinear regression. The data demonstrated a triphasic
curve fit with calculated half-lives of 0.38, 3.9, and 17.6 hours for the a, , and c
phases, respectively.
Table 2. Pharmacokinetics of 125I-ZME, ZME–TNF, TNF, and scFvMEL/
TNF.
Parameters Full-Length
IgG ZME
Chemical
Conjugate
ZME–TNF
Cytokine
TNF
Immunocytokine
scFvMEL/TNF
Molecular
mass (kDa)
160 190 51 135
T1/2a (hr) 1.39 1.20 0.45 0.38
T1/2 (hr) – – – 3.93
T1/2g (hr) 41.30 36.05 2.68 17.59
Vd (ml) 1.91 11.68 3.95 19.50
T1/2a = plasma half-life, a phase;T1/2 = plasma half-life, b phase; T1/2g = plasma
half-life, terminal phase; Vd = immediate apparent volume of distribution.
Table 3. Survival of Mice after Five Consecutive Administrations of
scFvMEL/TNF.
Total Dose/Mouse
(mg/kg)
Mice per
Group (n)
Deaths (%) Survivors (%)
16.7 4 100 0
8.3* 4 100 0
4.8y 4 25 75
4.0z 5 0 100
2.5 5 0 100
0.5 3 0 100
*The LD100 of scFvMEL/TNF in mice is approximately 8.3 mg/kg.
yThe LD25 of scFvMEL/TNF in mice is approximately 4.8 mg/kg.
zThe MTD of scFvMEL/TNF in mice is approximately 4.0 mg/kg.
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control groups dramatically increased with time (Figure 3). It
was noted that, although tumor GFP signals were not
detected in some mice, small tumors were still measurable
using a caliper. When monitored by caliper measurement,
all mice treated with either saline or scFvMEL alone had
rapid tumor growth. Treatment with scFvMEL plus rhuTNF
demonstrated moderate tumor growth inhibition probably
due to TNF effects. However, scFvMEL/TNF treatment dem-
onstrated potent antitumor activity, with three of five mice
being tumor-free on day 21 and with complete tumor
regression (five of five mice being tumor-free) on day 43.
There was no subsequent outgrowth of tumors from mice
rendered tumor-free up to the last day of measurement on
day 75 (Figure 4). These data show that scFvMEL/TNF,
compared to TNF alone or scFvMEL or scFvMEL plus TNF,
can target melanoma cells in vivo and can result in pro-
nounced and prolonged antimelanoma effects.
Discussion
Malignant melanoma is a primary example of a cancer that
is highly metastatic and responds poorly to various treat-
ments, including chemotherapy and g-irradiation [44]. Novel
therapeutic strategies targeting melanoma are currently un-
der development in several laboratories [45]. We previously
reported [4] a fusion construct, designated scFvMEL/TNF,
that is composed of the antibody scFvMEL, which recognizes
the surface domain of the gp240 antigen present in 80% of
human melanoma cells. The antibody-specific delivery of
TNF, compared to TNF alone, to the cell surface of mela-
noma cells resulted in augmented cytotoxicity. In addition,
we demonstrated that antibody–TNF chemical conjugates
and fusion constructs were capable of delivering TNF to tu-
mors in vivo [4,12]. In this study, we further demonstrated
that the fusion construct scFvMEL/TNF has potent antitumor
activity after in vivo administration. In addition, the esti-
mated MTD for the scFvMEL/TNF fusion construct (4 mg/kg)
was found to be almost 10-fold higher than the MTD re-
ported for TNF itself (0.3 mg/kg) [46], suggesting that
the targeted construct is capable of directing the active
TNF cytokine to tumor cells and away from tissue sites that
cause toxicity.
TNF is known to not only possess direct cytotoxicity
against tumor cells, but also induce tumor vessel disruption
[47]. However, systemic administration of TNF protein has
been shown to result in significant host toxicity without
significant antitumor effects [48,49]. A variety of strategies
have been suggested for the use of the antitumor properties
of this agent and for the simultaneous reduction of its sys-
temic side effects, including antibody-mediated delivery
[4,40] or transfer of the TNF gene into tumor cells [36].
TNF as a cytotoxic payload for targeted therapeutics has
undergone extensive preclinical evaluation by our group and
others [4,12,28,50–52]. More recently, the novel immuno-
cytokine scFv23/TNF targeting Her-2/neu–overexpressing
malignancies has been shown to sensitize TNF-resistant
Her-2/neu–overexpressing breast cancer cells to TNF-
induced apoptosis [53]. These data suggest that TNF tar-
geted to tumor cells, compared to that of TNF itself, may have
fundamental differences in the cellular effects exerted by
the fusion construct. Studies in our laboratory examining
the mechanistic effects of scFvMEL/TNF versus TNF alone
suggested that the fusion construct specifically inhibits
SAPK/JNK pathways in melanoma cells resistant to TNF,
whereas TNF itself does not [54]. Further studies detailing
other mechanistic differences between these two molecules
are still ongoing.
Antibodies for the targeted delivery of cytokines not only
provide for enhanced localization to tumor tissues after
in vivo administration but also possess the potential to
Figure 2. Average terminal body weight (TBW) and relative organ weights in
toxicology studies of scFvMEL/TNF. Five BALB/c mice per group were
injected intravenously daily for 5 days with 1-, 2-, 3-, and 4-mg/kg total doses
of scFvMEL/TNF, corresponding to 25%, 50%, 75%, and 100% of an estab-
lished MTD. The vehicle control group consisted of saline. Seven days after
the last injection (day 12), mice were sacrificed by exposure to CO2. The
TBW of each mouse was measured before the performance of a complete
necropsy, including the liver, kidneys, and spleen. The organ weight of indi-
vidual animals was measured before the organs were fixed by immersion in a
neutral-buffered 10% formalin solution. The relative organ weights (relative to
body weight) were calculated as percentage of control (organ weight/TBW 
100). scFvMEL/TNF causes a dose-related increase in relative spleen
weights (relative to body weight).
Table 4. Group Means for Hematologic Parameters.
Groups HGB
(g/dl)
HCT
(%)
White Blood
Cells (103 l1)
Red Blood
Cells (106 l1)
Platelets
(103 l1)
Segmenters
(%)
Lymphocytes
(%)
Monocytes
(%)
Eosinophils
(%)
Basophils
(%)
Saline 14.7 41.0 10.8 9.4 768 12.2 81.3 1.7 3.6 1.2
1 mg/kg 13.1 35.9 7.8 8.3 914 15.7 74.7 4.7 1.8 3.3
2 mg/kg 13.8 38.0 7.9 8.8 944 20.4 75.6 1.6 1.4 0.9
3 mg/kg 13.7 39.0 7.1 9.0 406 24.6 69.8 2.7 1.5 1.5
4 mg/kg 12.7 36.0 4.8 8.2 584 30.6 57.2 7.3 1.8 3.1
Reference
range
12.8–16.4 35.9–48.2 1.4–8.9 7.2–9.8 615–1802 1–35 54.8–92.4 1.5–9.7 1–6.6 0
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increase the plasma half-life of therapeutic agents [55].
As shown in this study, scFvMEL/TNF has a relatively
short serum half-life (17.6 hours) compared to mAb (ZME,
41.3 hours). The chemical conjugate ZME–TNF, consisting
of the full-length IgGantibodyZME-018 chemically coupled to
TNF, demonstrated a much longer serum half-life (36 hours),
thereby increasing the circulating time of biologically active
TNF. The scFvMEL/TNF fusion construct, compared to TNF
itself, therefore provides for a prolonged plasma half-life
(2.7 hours), and previous studies [4] examining the tissue
distribution of the construct in tumor xenograft models also
demonstrate impressive localization of the agent in gp240-
expressing tumors.
Because effective clinical management of solid tumors
such as melanoma generally requires prolonged treatment
regimens, the immunogenicity of this molecule is of con-
cern. The constant domain (murine framework) regions of
the scFvMEL molecule account for f37% of the total size
of the construct. By comparison, mouse/human chimeric
antibodies also contain 35% murine sequences. Therefore,
based on this analysis, we expect the immunogenicity of
the construct to be similar to that of chimeric antibodies. The
immunogenicity of an antibody–cytokine containing full-
length antibodies is due, at least in part, to the large size
of the antibody itself and the long circulation time of the
constructs. The serum half-life of the scFvMEL/TNF fusion
construct was much shorter than that of the chemical con-
jugate, suggesting that the single-chain immunocytokine, by
comparison, should be significantly less immunogenic due
to its small size and relatively rapid clearance kinetics from
the circulation. In addition to these properties, scFvMEL/
TNF demonstrated a Vd (19.5 ml) that is higher than those
of both TNF and chemical conjugate ZME–TNF, suggesting
its relatively greater distribution outside the vasculature.
Tissue distribution studies [4] of the scFvMEL/TNF construct
indicated that tumor localization of the construct occurs effi-
ciently by 72 hours. Concentrations of the fusion construct,
compared to those of free TNF, were shown to be highest
in tumor tissues. The tumor-targeting capability of the con-
struct, compared to that of TNF, may also account for the
increase in the apparent volume of distribution (Vd) of the
construct. In addition, the smaller size of the scFvMEL/TNF
construct, compared to that of the chemical conjugate ZME–
TNF, may be responsible for its comparatively facile extra-
vascular disposition. The short half-life observed with this
construct suggests that dosing intervals of 24 or 48 hours
appear to be optimal to achieving the maximal concentration
of the agent in tumor tissues.
Of critical importance to the eventual clinical develop-
ment of scFvMEL/TNF is an examination of MTD toxicity
profile and efficacy studies of this fusion construct in well-
characterized human melanoma xenograft models. The
MTD of the fusion construct scFvMEL/TNF was 0.8 mg/kg
daily for five consecutive days, corresponding to an MTD
of 4 mg/kg (total dose). It is important to note that the im-
pressive antitumor effects observed in vivo with the fusion
construct were obtained at a dose of 2.5 mg/kg, which is
approximately 60% of the MTD and is also below the NOAEL
dose (3 mg/kg) determined from our toxicology studies.
Our results indicate that neither significant adverse
effects nor organ toxicity was associated with intravenous
injections of scFvMEL/TNF at doses of up to 100% of the
MTD (4 mg/kg). The scFvMEL/TNF construct could be safely
administered at this schedule at doses of up to 75% of the
MTD (3.0 mg /kg). Although dose-related extramedullary
hematopoiesis was noted in the liver and the spleen, and
follicular cell (lymphoid) hyperplasia was noted in the spleen,
none of these lesions was considered an adverse effect.
Table 5. Group Means for Clinical Chemistry Parameters.
Groups Na
(mEq/l)
K
(mEq/l)
Ca+
(mg/dl)
PO4
(mg/dl)
TBIL
(mg/dl)
TP
(g/dl)
Alb
(g/dl)
Glob
(g/dl)
Alk
(IU/l)
Cr
(mg/dl)
BUN
(mg/dl)
AST
(IU/l)
ALT
(IU/l)
Saline 153.1 7.1 10.3 8.8 0.4 5.5 3.8 1.7 140 0.2 21.7 133 58
1 mg/kg 152.5 7.7 10.5 8.8 0.2 5.5 3.7 1.8 117 0.2 18.6 115 76
2 mg/kg 151.6 7.9 10.3 8.8 0.3 5.6 3.8 1.9 123 0.2 17.6 216 179
3 mg/kg 151.8 7.8 10.8 9.5 0.3 5.9 3.7 2.2 111 0.2 13.4 258 112
4 mg/kg 150.2 8.8 10.9 10.7 0.3 5.9 3.7 2.2 134 0.2 18.7 376 199
Reference
range
146–152 7–11 8–12 8.9–13 0–0.5 5.5–6 3–3.4 2.5–2.8 111–224 0–0.4 18–33 <410 <344
Table 6. Summary Incidence: scFvMEL/TNF–Related Organ Morphologic Lesions and Lesion Average Grades*.
Groups Liver, Extramedullary
Hematopoiesis, Increased
Lung, Thrombus, Fibrosed/
Recanalized, Singular
Spleen, Extramedullary
Hematopoiesis, Increased
Spleen, Follicular
Cell Hyperplasia
#P/Ty Grade #P/T Grade #P/T Grade #P/T Grade
Saline 2/5 1 0/5 2/5 1 2/5 1
1 mg/kg 1/5 1 0/5 5/5 1.5 5/5 2.8
2 mg/kg 4/5 1 0/5 5/5 2 5/5 3.2
3 mg/kg 5/5 1 0/5 5/5 4 5/5 3.4
4 mg/kg 5/5 1 3/5 1 5/5 4 5/5 4
*The incidence of the lesion in the group: Grade 1 = modest, rare 5 to 10 %; Grade 2 = mild, infrequent 10 to 20 %; Grade 3 = moderate, frequent 20 to 50 %; Grade
4 = severe, extensive > 50 %.
y#P/T, Numbers of positive mice /total mice
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Extramedullary hematopoiesis is the proliferation of erythro-
cytes, myelocytes, and megakaryocytes in the spleen and
the liver, primarily. It occurs spontaneously in mice and has
a higher incidence in female mice. The spleen is a major
hematopoietic organ in mice. The increased incidence and
severity of extramedullary hematopoiesis in mice can be
caused by anything that will stimulate hematopoiesis. Most
proinflammatory cytokines stimulate hematopoiesis through
different growth factors, as do conditions that produce anoxia
such as hemolysis or bone marrow toxicity. In this toxicity
study, the specific cause of extramedullary hematopoiesis is
unknown, but it may be related to the proinflammatory
properties of TNF. Follicular lymphoid hyperplasia is an
indication of the immunogenicity of this protein in mice.
Figure 3. Antitumor activity of scFvMEL/TNF in A375GFP tumor xenografts monitored by the Xenogen IVIS 200 Imaging System. Nude mice bearing established
(50 mm3) human melanoma (A375GFP) tumors stably transfected with GFP growing in the right flank were treated intravenously with either saline (control),
scFvMEL (2.5 mg/kg), scFvMEL (0.2 mg/kg) plus TNF (0.2 mg/kg), or scFvMEL/TNF (2.5 mg/kg; total dose) for five consecutive days. The tumors were monitored
using the Xenogen IVIS 200 Imaging System after mice had been anesthetized once with Nembutal (50 mg/kg, i.p.) a week after treatment. On treatment with
scFvMEL/TNF, tumor GFP signals (arrows) were not detected in three of five mice on day 16, in four of five mice on day 22, and in five of five mice on day 36,
respectively, whereas tumor GFP signals dramatically increased with time in all mice in the saline and scFvMEL control groups, indicating tumor growth.
Figure 4. Antitumor activity of scFvMEL/TNF in A375GFP tumor xenografts asmonitored by caliper measurement. Nudemice bearing humanmelanoma (A375GFP)
tumors were treated intravenously with either saline (control), scFvMEL (2.5 mg/kg), scFvMEL (0.2 mg/kg) plus rhuTNF (0.2 mg/kg), or scFvMEL/TNF (2.5 mg/kg;
total dose) for five consecutive days (arrows). The treatment of mice bearing established (30–50 mm3) tumors with scFvMEL/TNF at a dose of 2.5 mg/kg resulted
in potent tumor suppression and complete tumor regression of all lesions (with three of fivemice being tumor-free on day 21, and with five of five mice being tumor-free
on day 43). In contrast, all mice treated with either saline, scFvMEL alone, or scFvMEL plus TNF showed rapid tumor growth.
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Immunogenicity for humans needs to be addressed in a
more relevant species. In addition, we found no significant
changes in hematologic parameters or changes in clinical
chemistry parameters in mice even when they were treated
at 100% of the MTD. A single recanalized thrombus in lung
tissues was observed in three of five mice at MTD level.
These thrombi occurred in only one vessel and did not com-
promise pulmonary function; however, they are considered
biologically adverse and, for this reason, NOAEL was
assessed at the 3-mg/kg (75% MTD) dose level. Therefore,
the safe level for a phase I trial is well below MTD level. The
cause of the thrombosis is speculative and may be related to
the proinflammatory properties of TNF.
The MTD of scFvMEL/TNF (4 mg/kg) in mice was found
to be significantly higher than that of rhuTNF alone (0.3 mg/
kg) [46]. The causes of death in animals treated with 4.8
(LD25), 8.3 (LD100), and 16.7 mg/kg scFvMEL/TNFmay have
been related to the proinflammatory properties of huTNF.
Studies recently demonstrated that rhuTNF induced severe
toxicity at the MTD because intravenously administered TNF
leads to the destruction of the normal tissue microvascula-
ture [46,56], resulting in vascular congestion and hemor-
rhagic injury in normal organs such as the gastrointestinal
tract and the thyroid gland. In addition, ulcers induced by
rhuTNF were sufficient to cause lethal toxicity [46]. How-
ever, in the present study, scFvMEL/TNF showed no signif-
icant normal organ injury in mice despite its higher antitumor
potency at 60% MTD. Thus, scFvMEL/TNF appears to have
more selective activity toward tumors, compared with a
rather nonspecific toxicity profile for rhuTNF.
Thus, careful assessment of the pharmacokinetics of the
scFvMEL/TNF construct has provided a rationale for design-
ing an optimal administration schedule. Assessment of the
therapeutic efficacy of this schedule demonstrates impres-
sive antitumor effects against well-established melanoma
xenografts. Efficacy studies, combined with histopathology,
clinical chemistry, and effects on clinical chemistry parame-
ters, provide a rationale for designing phase I trials in pa-
tients with gp240-positive tumors such as melanoma and
lobular breast cancer.
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